HR 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 1:19 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill, the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, aims to extend and update the existing Accelerating Access to Critical Therapies for ALS Act through 2031. It primarily reauthorizes the act’s provisions, including funding for ALS research and specific program enhancements. The bill also introduces changes to improve the grant review process and requires the FDA to publish a report on its action plan for rare neurodegenerative diseases, building upon a previous plan and assessing its impact.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.